14- Treatment of cancer (radiotherapy, immunotherapy and surgery) Flashcards
Radiotherapy
Aim:
to deliver carefully calculated doses of radiation to cancer cell, whilst minimising the radiation exposure to surrounding tissues -> overall aim to achieve a high rate of local tumour control with a low risk of complications
how radiotherapy is used in treatment of cancer
As a primary treatment
- i.e. sole radical treatment
- e.g. prostate cancer
In conjunction with surgery
- Neoadjuvant – prior to surgery -shrink a tumour before surgical resection
- Intraoperative- during surgery
- Adjunction- post surgery
Can also be administer alongside systemic therapies
Palliative treatment
- Radiotherapy to a tumour causing spinal cord compression -> reducing neuropathic symptoms
- Radiotherapy to bony mets to reduce pain
40% of all patients cured/ 50% of all cancer patients will benefits from receiving radiotherapy
how radiotherapy works
- Used high energy radiation to eliminate cancer cells
- Radiation used is ionising, meaning it forms ions which then deposit energy into the cells of the tissues they pass through
Causes cell death in one of 2 ways - Apoptosis by causing DNA damage
- Preventing cancer cell proliferation, by causing single and dsDNA breaks (mitotic cell death)
*Cancer cells have a reduced capacity to repair DNA in comparison to healthy cells
*
Dosage of radiotherapy
- Delivered in fractions (sessions) until the total prescribed cumulative disease has been delivered
- Amount of energy absorbed in measured in Grays (Gy)
- Fractions help reduce the risk of acute tissue reactions and minimises damage to normal cells (which are able to undergo repair between fractions)
radiotherapy involves
planning and simulation
Planning
- Involves using imaging to determine where the radiation is to be aimed
- Aim to maximise radiation dose to anormal cells and monimise exposure to normal cells
- Margins are placed around the gross tumour volume to encompass microscopic disease spread
- Aim is to delivered higher dosing to the tumour volumes and comparably lower dosing to vulnerable anatomical structures such as the bladder, small bowel, rectum and femoral head
Simulation
- A custom radiation planning appointment- places patient in a reproducible position for the radiotherapy
- Ct allows relevant anatomy to be viewed from the direction of the radiation beam
- Once all info obtained, small tattoos may be placed on the patient to line up with laser beams in the treatment room
- Immobilises and moulds are also used to maintain patient in the same position so that the exact position can be recreated in each session
2 primary methods of delivering radiation
External beam radiation - most common
Systemic
others: Internal radiation/ brachytherapy
External beam radiation- most common
Delivered form outside the body by aiming high energy rays (e.g. protons, photons, particle radiation) towards the cancers location
Systemic
Radioactive substance injected/swallowed e.g. iodine radiation for thyroid cancer
Internal radiation/ brachytherapy
- Uses radioactive sources inc catheter or seeds to delivered radiation from inside the body directly to the tumour site
- Boosts treatment or primary treatment
- Benefits: since radiation delivered directly to the tumour, surrounding healthy tissues is exposed to a relatively small dose
- E.g. cervical and prostate cancer
Side effects of radiotherapy
Can significantly impact patients quality of life and limit doses of radiation able to be delivered.
- Usually localised side effects compared to systemic therapies like chemo and immunotherapy
Early side effects (within 3 months) of radiotherapy
That manifest within a few weeks of completing course- tend to resolve within a few weeks (reversible)
- Skin reactions
o Erythema, desquamation
- Fatigue
- Mucositis
- Diarrhoea
- Nausea
Late side effects of radiotherapy
Occurs months to years after course of radiation- tend to be irreversible
Excessive extracellular matrix, deposition of collagen and fibrinogenesis play a key role in aetiology
- Radiation induced fibrosis
- Atrophy
- Neural or vascular damage
- Range of endocrine effects (diabetes, hypothyroidism)
Small risk of inducing secondary malignancy due to associated DNA damage
Radiotherapy prescription
- Dose in Gray (the unit of absorbed dose, joule/kg)
- Divided into fractions (no of sessions) to minimize side effects
- Typical prescriptions:
- 50 Gy / 25 fractions
- 8 Gy / single fraction
- Target to GTV (gross tumour volume) or CTV (clinical target volume)
- Side effects local to site treated
- Aim to avoid interruptions – need a good reason to miss treatment
Radiosensitisers
- Temozolamide
–>Oral chemo for GBM - Capecitabine
–> Oral chemo for Colorectal Cancer - Cisplatin
–>Wide range of uses (Lung, teratoma, gynae, H&N) - Cetuximab –Monoclonal antibody
–>Given if prior Cisplatin or cannot tolerate Cisplatin - 5FU
–> GI tract tumours
Immunotherapy
- Aim it to boost natural immune defences so it can recognise, target and destroy cancer cells
- Most commonly refers to checkpoint inhibitors
Categorisation of immunotherapy
- Checkpoint inhibitors
- Adoptive cell therapy
- Cancer vaccine
- Cytokines
- Oncolytic virus therapy
- Monoclonal antibodies
–> May stop a cancer cell from growing but also trigger immune system to attack and kill cancer cells
Checkpoint inhibitors
Background
Checkpoints are receptors on the surface of T cell. They suppress T cell immune response to prevent T cells from attacking normal cells
- Can be used as single agents or in combination
- Types
o PDL1 receptor inhibitors
o PD1 rector inhibitors
o CTLA-4 receptor inhibitors
PD-1/PD-L1 immune checkpoint
e.g. Nivolumab, Pembrolizumab
Used in melanoma, lung, renal cancers
- Inhibitors of PD-1 and PD-L1 disrupt the PD-1/PD-L1 interaction and allow T effector cells to become activated and kill tumour cells. From this we have developed PD-1 inhibitors Nivolumab and Pembrolizumab and PD-L1 inhibitors which are just unpronouncable!
- PD-1 is a negative regulator of T-cell activity that inhibits T-cell activity at multiple stages of the immune system. Binding of the T-cell’s PD-1 to PD-L1 or PD-L2 on the cancer cell leads to inactivation of the T-cell so it can not kill the tumour cells.
CTLA4 inhibitors
- Ipilimumab
- Used in melanoma
Adoptive cell therapy
- T cells are isolated from the patients.
- Modification and multiplication of those cells in the laboratory and then re-injection back to the patient circulation
**- CAR-T – **chimeric antigen receptor T-cell – therapy - Very expensive! One session = £280000
- Licensed in the UK for B cell CLL and lymphoma (DLBCL)